Eli Lilly: Trump's Most Favored Nation Pricing Policy to Impact Weight-Loss Drug European Launch
Taylor Wilson
Eli Lilly plans to launch its oral weight-loss drug in Europe from late 2026, but the Trump administration's most-favored-nation pricing framework is squeezing reimbursement negotiations and pushing the company toward direct-to-consumer channels first.
What is "most-favored-nation" drug pricing?
MFN pricing — a framework tying U.S. net drug prices to income-adjusted prices in other countries — creates one binding rule: the cheaper Europe pays, the less Lilly can charge in the U.S.
This means → Lilly can no longer trade lower European prices for broader market access, because every concession in Europe directly cuts American profit.
Lilly has already signed an agreement with the Trump administration committing to MFN pricing on new drugs.
How does Lilly plan to work around this?
Most obesity treatments in Europe are paid out-of-pocket, not covered by public health systems. Lilly will therefore launch first through telehealth companies, e-commerce platforms, and direct-to-patient channels.
In plain terms = sell to consumers willing to pay, without waiting for government reimbursement talks to conclude.
This replicates the consumer-driven obesity business Lilly already built in the U.S. — public reimbursement proceeds in parallel but is not a precondition.
How much room is left for public reimbursement?
Patrik Jonsson, Lilly's executive VP for international, told Reuters the company will seek reimbursement prices consistent with its understanding of the MFN framework, but added: "Where possible, public coverage remains the goal."
This means → Lilly has not abandoned the insurance channel, but MFN has raised the floor — the lowest acceptable reimbursement price is now higher than before.
European governments face a binary: accept higher reimbursement prices, or watch weight-loss drugs circulate only in the self-pay market.
What does this mean for the wider industry?
Drugmakers are already warning that low European prices will increasingly erode returns in the lucrative U.S. market. MFN has tied the two markets' prices together.
This reflects a broader shift — multinational pharma is moving from "cut price for volume" to "protect price first" in Europe.
Whether Lilly can strike an acceptable reimbursement deal under MFN constraints will be the first major test case for how this framework reshapes every multinational drugmaker's European strategy.
Content is for reference only, not financial advice.